Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Pharming Group N.V (PHAR) EBT Margin: 2020-2025

Historic EBT Margin for Pharming Group N.V (PHAR) over the last 4 years, with Sep 2025 value amounting to 92.73%.

  • Pharming Group N.V's EBT Margin rose 8724.00% to 92.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 40.76%, marking a year-over-year increase of 5051.00%. This contributed to the annual value of -2.90% for FY2024, which is 103.00% down from last year.
  • As of Q3 2025, Pharming Group N.V's EBT Margin stood at 92.73%, which was up 123.62% from -392.67% recorded in Q2 2025.
  • Pharming Group N.V's EBT Margin's 5-year high stood at 92.73% during Q3 2025, with a 5-year trough of -392.67% in Q2 2025.
  • Over the past 3 years, Pharming Group N.V's median EBT Margin value was -6.23% (recorded in 2023), while the average stood at -37.80%.
  • Over the last 5 years, Pharming Group N.V's EBT Margin had its largest YoY gain of 8,724bps in 2025, and its largest YoY loss of 37,009bps in 2025.
  • Quarterly analysis of 5 years shows Pharming Group N.V's EBT Margin stood at 6.44% in 2021, then surged by 131bps to 7.75% in 2022, then crashed by 643bps to 1.32% in 2023, then skyrocketed by 883bps to 10.15% in 2024, then spiked by 8,724bps to 92.73% in 2025.
  • Its EBT Margin was 92.73% in Q3 2025, compared to -392.67% in Q2 2025 and 10.15% in Q4 2024.